

6.3157% p.a. ZKB Reverse Convertible Defensive on worst of Novartis AG/Givaudan AG/Flughafen Zuerich AG/Lindt & Sprüngli AG

30/07/2025 - 30/01/2026 | Swiss Security Code 144 653 221

Summary

This Summary is to be understood as an introduction to the present Final Terms. Any investment decision in relation to the products must be based on the information contained in the Base Prospectus and in these Final Terms in their entirety and not on the Summary. In particular, each investor should consider the risk factors contained in these Final Terms and in the Base Prospectus.

The Issuer can only be held liable for the content of this Summary if the Summary is misleading, incorrect or contradictory when read together with the other parts of the Final Terms and the Base Prospectus.

Information on the securities	
Type of product:	ZKB Reverse Convertible on worst of
SSPA category:	Reverse Convertible (1220, acc. Swiss Structured Products Association)
ISIN:	CH1446532215
Issuer:	Zürcher Kantonalbank Finance (Guernsey) Limited, Guernsey
Underlyings:	Novartis AG/Givaudan AG/Flughafen Zuerich AG/Lindt & Sprüngli AG
Initial Fixing Date:	23/07/2025
Payment Date:	30/07/2025
Final Fixing Date:	23/01/2026
Redemption Date:	30/01/2026
Cap Level:	88.00% of the Initial Fixing Value
Mode of settlement:	cash
Coupon:	6.3157% p.a. of Denomination
Information on the offer and admission to trading	
Place of the offer:	Switzerland
Issue amount/	CHF 100,000, without the right to increase/CHF 20,000
Denomination/Trading	Denomination per product/CHF 20,000 or multiples thereof
units:	
Issue price:	100.00% of Denomination (CHF 20,000)
Information on listing:	The product shall not be listed on an exchange.

Final Terms

**Derivative
Category/Designation
Regulatory Notification**

Issuer

Keep-Well Agreement

1. Product specific conditions and product description

Yield Enhancement / Reverse Convertible (1220, acc. Swiss Structured Products Association)

This product does not constitute a collective investment scheme within the meaning of the Swiss Federal Act on Collective Investment Schemes (CISA) and it is not subject to authorisation or supervision by FINMA. The issuer risk is borne by investors.

Zürcher Kantonalbank Finance (Guernsey) Limited, Saint Peter Port, Guernsey
Zürcher Kantonalbank Finance (Guernsey) Limited is a wholly owned and fully consolidated subsidiary of Zürcher Kantonalbank. It is not subject to any direct prudential supervision neither in Guernsey nor in Switzerland and does not have a rating.

Zürcher Kantonalbank Finance (Guernsey) Limited is a fully owned subsidiary of Zürcher Kantonalbank. Zürcher Kantonalbank obtains the following three ratings: Standard & Poor's: AAA, Moody's: Aaa, Fitch: AAA. Zürcher Kantonalbank is committed to Zürcher Kantonalbank Finance (Guernsey) Limited with sufficient financial means, allowing to satisfy any claims of its creditors in due time. The full text of the Keep-Well Agreement, which is subject to Swiss law, can be found in the publicly available Base Prospectus.

Lead Manager, Paying Agent, Exercise Agent and Calculation Agent	Zürcher Kantonalbank, Zurich
Swiss Security Code/ISIN	144 653 221/CH1446532215
Issue amount/ Denomination/Trading units	CHF 100,000, without the right to increase/CHF 20,000 Denomination per product/CHF 20,000 or multiples thereof
Issue price	100.00% of Denomination (CHF 20,000)
Currency	CHF
Currency Hedge	No
Mode of settlement	cash

Underlying(s)

Underlying	Type of Underlying Domicile	ISIN Bloomberg	Reference exchange/ Price source
Novartis AG	registered share Switzerland	CH0012005267 NOVN SE Equity	SIX Swiss Exchange
Givaudan AG	registered share Switzerland	CH0010645932 GIVN SE Equity	SIX Swiss Exchange
Flughafen Zuerich AG	registered share Switzerland	CH0319416936 FHZN SE Equity	SIX Swiss Exchange
Lindt & Sprüngli AG	participation certificate Switzerland	CH0010570767 LISP SE Equity	SIX Swiss Exchange

Information on Levels

Underlying	Initial Fixing Value	Cap Level	Ratio
Novartis AG	CHF 92.90	CHF 81.752 (88.00% of the Initial Fixing Value)	n/a
Givaudan AG	CHF 3,644.00	CHF 3,206.72 (88.00% of the Initial Fixing Value)	n/a
Flughafen Zuerich AG	CHF 232.30	CHF 204.424 (88.00% of the Initial Fixing Value)	n/a
Lindt & Sprüngli AG	CHF 12,410.00	CHF 10,920.80 (88.00% of the Initial Fixing Value)	n/a

* Local taxes, transactions fees and foreign commissions are, if applicable, included in the Initial Fixing Value of each component and are thus borne by the holders of the structured product. This applies particularly, though not exclusively, when exercising rights associated with the structured product and/or a Rebalancing.

Coupon	6.3157% p.a. per Denomination CHF 20,000 Interest part: 0.00%; Premium part: 3.1579% The Coupons are paid out on the respective Coupon Date regardless of the performance of the Underlyings.
---------------	---

Coupon Date(s)/ Coupon Payment(s)	Coupon Date _t *	Coupon Payment _t
t = 1	30/10/2025	1.578925%
t = 2	30/01/2026	1.578925%

* modified following business day convention

Coupon Calculation Method

Initial Fixing Date/ Initial Fixing Value	30/360 Novartis AG: Theoretically calculated price on 23/07/2025, 14:54:40 CET Givaudan AG: Theoretically calculated price on 23/07/2025, 14:54:40 CET Flughafen Zuerich AG: Theoretically calculated price on 23/07/2025, 14:54:40 CET Lindt & Sprüngli AG: Theoretically calculated price on 23/07/2025, 14:54:40 CET
--	---

Payment Date	30/07/2025
Last Trading Date	23/01/2026
Final Fixing Date/ Final Fixing Value	Novartis AG: Closing price on SIX Swiss Exchange on 23/01/2026 Givaudan AG: Closing price on SIX Swiss Exchange on 23/01/2026 Flughafen Zuerich AG: Closing price on SIX Swiss Exchange on 23/01/2026 Lindt & Sprüngli AG: Closing price on SIX Swiss Exchange on 23/01/2026

Redemption Date	30/01/2026
------------------------	------------

Underlyings

on www.bloomberg.com. The latest annual reports can be accessed directly via the companies' website.

Notifications

Any notice by the Issuer in connection with this product, in particular any notice in connection with modifications of the terms and conditions will be validly published on the website www.zkb.ch/finanzinformationen. The Swiss security code search button will lead you directly to the relevant product.

**Governing Law/
Jurisdiction**

Swiss Law/Zurich

**Profit and Loss Expectations at
Maturity****2. Profit and Loss Expectations at Maturity**

ZKB Reverse Convertible Defensive on worst of

Value	Percent	Redemption	Performance in %
Worst Underlying			
CHF 65.03	-30%	CHF 16540.66	-17.30%
CHF 74.32	-20%	CHF 18813.39	-5.93%
CHF 83.61	-10%	CHF 20631.57	3.16%
CHF 92.9	0%	CHF 20631.57	3.16%
CHF 102.19	10%	CHF 20631.57	3.16%
CHF 111.48	20%	CHF 20631.57	3.16%
CHF 120.77	30%	CHF 20631.57	3.16%

If the Final Fixing Value of all Underlyings is at or above the Cap Level, the performance of the product is always given by the Coupons paid out during the term. However, if the Final Fixing Value of at least one Underlying is below the Cap Level, the investor receives a cash repayment corresponding to the Denomination divided by the Cap Level and multiplied by the Final Fixing Value of the worst performing Underlying. Therefore, the investor may suffer a partial or total loss. The acquisition price is 88.00% of the Initial Fixing Value (Cap Level), which means that the performance of the product is less negative than the performance of the Underlying. This negative performance is reduced by the guaranteed Coupons paid out during the term.

The table above is valid at maturity only and is by no means meant as a price indication for the present product throughout its lifetime. Additional risk factors may have a significant impact on the value of the product during the term. The price quoted on the secondary market can therefore deviate substantially from the above table. For this table it was assumed, that Novartis AG was the worst performing Underlying. This selection is just a representative example of the possible alternatives. Currency risks between the Underlyings and the Product are not considered in the table.

3. Material Risks for Investors**Issuer Risk**

Obligations under these products constitute direct, unconditional and unsecured obligations of the Issuer and rank pari passu with other direct, unconditional and unsecured obligations of the Issuer. The value of the product not only depends on the performance of the Underlying and other developments in the financial markets, but also on the solvency of the Issuer, which may change during the term of this product.

Specific product risks

Structured products are complex financial instruments, which entail considerable risks and, accordingly, are only suitable for investors who have the requisite knowledge and experience and understand thoroughly the risks connected with an investment in these structured products and are capable of bearing the economic risks. The loss potential of an investment in ZKB Reverse Convertible Defensive on worst of is limited to the difference between the purchase price and the cash redemption amount as defined in 'Redemption Method'. The Coupon, which is paid out in any case, reduces the loss of the product compared to a direct investment in the worst performing Underlying. The product is denominated in CHF. If the investor's reference currency differs from the CHF, the investor bears the risk between the CHF and his reference currency.

4. Additional Terms**Modifications**

If an extraordinary event as described in the Base Prospectus occurs in relation to an Underlying/Component of the Underlying or if any other extraordinary event occurs, which makes it impossible or particularly cumbersome for the Issuer, to fulfill its obligations under the products or to calculate the value of the products, the Issuer shall at its own discretion take all the necessary actions and, if necessary may modify the terms and conditions of these products at its own discretion in such way, that the economic value of the products after occurrence of the extraordinary event corresponds, to the extent possible, to the economic value of the products prior to the occurrence of the extraordinary event.

Change of Obligor

The Issuer is entitled at all times and without the consent of the investors to assign in whole (but not in part) the rights and claims under individual products or all of them to a Swiss or

foreign subsidiary, branch or holding company of the Zürcher Kantonalbank (the "New Issuer") to the extent that (i) the New Issuer assumes all of the obligations arising out of the assigned products which the previous Issuer owed in respect of these products, (ii) the Zürcher Kantonalbank enters into a Keep-Well Agreement with the New Issuer with terms equivalent to the one between the Zürcher Kantonalbank and Zürcher Kantonalbank Finance (Guernsey) Limited, (iii) the New Issuer has received from the supervisory authorities of the country in which it is domiciled all necessary approvals for the issue of products and the assumption of the obligations under the assigned products.

Market Disruptions**Prudential Supervision**

Compare specific provisions in the Base Prospectus.

As a bank within the meaning of the Swiss Federal Act on Banks and Savings Banks (BankG; SR 952.0) and a securities firm within the meaning of the Swiss Federal Act on Financial Institutions (FinIAG; SR 954.1), Zürcher Kantonalbank is subject to the prudential supervision of FINMA, Laupenstrasse 27, CH-3003 Bern, <https://www.finma.ch>.

Recording of Telephone Conversations

Investors are reminded, that telephone conversations with trading or sales units of the Zürcher Kantonalbank are recorded. Investors, who have telephone conversations with these units consent tacitly to the recording.

Further indications

This document constitutes neither an offer nor a recommendation or invitation to purchase financial instruments and can't replace the individual investor's own judgement. The information contained in this document does not constitute investment advice but is intended solely as a product description. An investment decision should in any case be made on the basis of these Final Terms and the Base Prospectus. Particularly, before entering into a transaction, the investor should, if necessary with the assistance of an advisor, examine the conditions for investment in the product in consideration of his personal situation with regard to legal, regulatory, tax and other consequences. Only an investor who is aware of the risks of the transaction and has the financial capacity to bear any losses should enter into such transactions.

Material Changes

Since the end of the last financial year or the date of the interim financial statements, there have been no material changes in the assets, financial or revenue position of the Issuer and Zürcher Kantonalbank.

Responsibility for the Final Terms

Zürcher Kantonalbank, Zurich, and Zürcher Kantonalbank Finance (Guernsey) Limited, Guernsey, assume responsibility for the content of these Final Terms and hereby declare that, to their knowledge, the information contained in these Final Terms is correct and no material circumstances have been omitted.

Zurich, 23/07/2025